Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

How will RNAi facilitate drug development?

Steven Bartz1, Aimee L Jackson

  • 1Rosetta Inpharmatics, LLC., a wholly owned subsidiary of Merck & Co., Inc., 401 Terry Avenue North, Seattle, WA 98109, USA. steven_bartz@merck.com

Science'S STKE : Signal Transduction Knowledge Environment
|August 4, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Distribution of divalent small interfering RNA into neurons of sensory ganglia produces selective, durable knockdown of Nav1.7 and strong analgesia.

Pain·2026
Same author

Divalent siRNA for prion disease.

Nucleic acids research·2026
Same author

Divalent siRNA for prion disease.

bioRxiv : the preprint server for biology·2026
Same author

Durable suppression of seizures in a preclinical model of KCNT1 genetic epilepsy with divalent small interfering RNA.

Epilepsia·2025
Same author

Systematic classification and comparison of maternal and obstetrical complications following 2 different methods of fetal surgery for the repair of open neural tube defects.

American journal of obstetrics and gynecology·2023
Same author

Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>.

Clinical cancer research : an official journal of the American Association for Cancer Research·2020
Same journal

Identification of redox-active cell-surface proteins by mechanism-based kinetic trapping.

Science's STKE : signal transduction knowledge environment·2007
Same journal

Image correlation spectroscopy.

Science's STKE : signal transduction knowledge environment·2007
Same journal

Studies of SARM1 uncover similarities between immune and neuronal responses to danger.

Science's STKE : signal transduction knowledge environment·2007
Same journal

A discrete signaling function for an inositol pyrophosphate.

Science's STKE : signal transduction knowledge environment·2007
Same journal

Putting on the RITz.

Science's STKE : signal transduction knowledge environment·2007
Same journal

Type I interferons as anti-inflammatory mediators.

Science's STKE : signal transduction knowledge environment·2007
See all related articles

RNA interference (RNAi) screens enable large-scale functional genomics in human cells for identifying therapeutic molecular targets. This technology revolutionizes drug discovery by advancing target identification and validation for human diseases.

Area of Science:

  • Genomics
  • Molecular Biology
  • Drug Discovery

Background:

  • Effective drug development hinges on identifying molecular targets for human diseases.
  • Traditional target identification methods, such as genetic screens in model organisms and lower-throughput mammalian assays, have limitations.

Purpose of the Study:

  • To highlight the transformative potential of RNA interference (RNAi) screens in human cells for functional genomics.
  • To discuss the impact of RNAi screens on target identification and validation in drug discovery.

Main Methods:

  • Utilizing RNA interference (RNAi) for large-scale functional genomics in human cells.
  • Performing RNAi screens to identify novel genes involved in critical cellular processes.

Main Results:

Related Experiment Videos

  • RNAi screens facilitate unprecedented scale and throughput for target identification in human systems.
  • Studies report successful RNAi screens implicating novel genes in apoptosis, cell division, and drug resistance.

Conclusions:

  • RNAi screens represent a breakthrough technology poised to revolutionize drug development.
  • Careful consideration of interpretation issues is warranted when utilizing RNAi screening results for target validation.